Citations Appearing in 1999

  1. Acosta, E.P., K. Henry, L. Baken, L.M. Page and C.V. Fletcher. Indinavir concentrations and antiviral effect. Pharmacotherapy 19(6):708-712, 1999.
  2. Amantea, M.A., R.A. Bowden, A. Forrest, P.K. Working, M.S. Newman and R.D. Mamelok. The population pharmacokinetics of amphotericin B colloidal dispersion in patients receiving bone marrow Transplants. Chemotherapy 45:48-53, 1999.
  3. Amantea, M., M.S. Newman, T.M. Sullivan, A. Forrest and P.K. Working. Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs. Human Experimental Toxicology 18(1):17-26, 1999.
  4. Auclair, B. and M.P. Ducharme. Piperacillin and tazobactam exhibit linear pharmacokinetics after multiple standard clinical doses. Antimicrobial Agents and Chemotherapy 43(6):1465-1468, 1999.
  5. Baker, S.D., M. Wirth, P. Statkevich, P. Reidenberg, K. Alton, S.E. Sartorius, M. Dugan, D. Cutler, V. Batra, L.B. Grochow, R.C. Donehower and E.K. Rowinsky. Absorption, metabolism, and excretion of C-14-temozolomide following oral administration to patients with advanced cancer. Clinical Cancer Research 5(2):309-317, 1999.
  6. Balthasar, J.P. Bioequivalence and bioequivalency testing. American Journal of Pharmaceutical Education 63(2):194-198, 1999.
  7. Baselga, J., D. Tripathy, J. Mendelsohn, S. Baughman, C.C. Benz, L. Dantis, N.T. Sklarin, A.D. Seidman, C.A. Hudis, J. Moore, P.P. Rosen, T. Twaddell, I.C. Henderson and L. Norton. Phase II study of weekly intravenoustrastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Seminars in Oncology 26(4):78-83, 1999.
  8. Bathe, M. and R.D. Kamm. A fluid-structure interaction finite element analysis of pulsatile blood flow through a compliant stenotic artery. Journal of Biomechanical Engineering-Transactions of the ASME 121(4):361-369, 1999.
  9. Bauer, K.S., W.D. Figg, J.M. Hamilton, E.C. Jones, A. Premkumar, S.M. Steinberg, V. Dyer, W.M. Linehan, J.M. Pluda and E. Reed. A pharmacokinetically guided phase II study of carboxyamido-triazole in androgen-independent prostate cancer. Clinical Cancer Research 5(9):2324-2329, 1999.
  10. Bauer, R.J., R. Dedrick, M. White, M. Murray and M. Garovoy. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. Journal of Pharmacokinetics and Biopharmaceutics 27(4): 397-420, 1999.
  11. Bauer, R.J., N.Wedel, N. Havrilla, M. White, A. Cohen and S.F. Carroll. Pharmacokinetics of a recombinant modified amino terminal fragment of bactericidal/permeability- increasing protein (rBPI21) in healthy volunteers. Journal of Clinical Pharmacology 39(11):1169-1176, 1999.
  12. Belani, C.P., C.M. Kearns, E.G. Zuhowski, K. Erkmen K; D. Hiponia, D. Zacharski, C. Engstrom, P.K. Ramanathan, M.J. Capozzoli, J. Aisner and M.J. Egorin. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and Carboplatin in patients with metastatic non-small-cell lung cancer. Journal of Clinical Oncology 17(2):676-684, 1999.
  13. Bernstein, M.L., S. Baruchel, S. Devine, N. Markoglou, I.W. Wainer, M. Williams, S. Blaney, A. Moghrabi, N. Winick and T. Vietti. Phase I and pharmacokinetic study of CI-980 in recurrent pediatric solid tumor cases: A pediatric oncology group study. Journal of Pediatric Hematology Oncology 21(6):494-500, 1999.
  14. Caponigro, F., A. Avallone, H. McLeod, G. Carteni, F. De Vita, R. Casaretti, J. Morsman, R. Blackie, A. Budillon, L. De Lucia, A. Gravina, G. Catalano, P. Comella and G. Comella. Phase I and pharmacokinetic study of Tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer. Clinical Cancer Research 5(12):3948-3955, 1999.
  15. Chakraborty, A., W. Krzyzanski and W.J. Jusko.Mathematical modeling of circadian cortisol concentrations using indirect response models: Comparison of several methods. Journal of Pharmacokinetics and Biopharmaceutics 27(1):23-43, 1999.
  16. Chakraborty, A., R.A. Blum, S.M. Mis, D.L. Cutler and W.J. Jusko. Pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers. Journal of Clinical Pharmacology 39(6):624-635, 1999.
  17. Chicco, D., I. Grabnar, A. Skerjanec, D. Vojnovic, V. Maurich, N. Realdon, E. Ragazzi, A. Belic, R. Karba and A. Mrhar. Correlation of in vitro and in vivo paracetamol availability from layered excipient suppositories. International Journal of Pharmaceutics 189(2):147-160, 1999.
  18. Chow, F.S., A. Sharma and W.J. Jusko. Modeling interactions between adrenal suppression and T-helper lymphocyte traficking during multiple dosing of methylprednisolone. Journal of Pharmacokinetics and Biopharmaceutics 27(6):559-575, 1999.
  19. Clarke, K.G., T.L. Odom-Maryo, L.E. Williams, A. Liu, G. Lopatin, J. Chou, G.M. Farino, A.A. Raubitschek and J.Y.C.Wong. Intrapatient consistency of imaging biodistributions and their application to predicting therapeutic doses in a phase I clinical study of Y-90-based radioimmunotherapy. Medical Physics 26(5):799-809, 1999.
  20. Cobelli, C., A. Caumo and M. Omenetto. Minimal model S-G overestimation and S-I underestimation: improved accuracy by a Bayesian two-compartment model. American Journal of Physiology-Endocrinology and Metabolism 277(3):E481-E488, 1999.
  21. Davis, C.B., L.P. Tobia, D.C. Kwok, C.M. Oishi, N. Kheterpal, T.W. Hepburn, L.J. Benincosa, F.S. Chow and W.J. Jusko. Accumulation of antibody-target complexes and the pharmacodynamics of clotting after single intravenous administration of humanized anti-factor IX monoclonal antibody to rats. Drug Delivery 6(3):171-179, 1999.
  22. Duffull, S.B., E.J. Begg and J.J. Deely. Development of a general method of limited sampling for the determination of A UC for a drug that displays two-compartment pharmacokinetics. European Journal of Clinical Pharmacology 55(3):213-219, 1999.
  23. Egorin, M.J., Z.M. Yuan, D.L. Sentz, K. Plaisance and J.L. Eiseman. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Cancer Chemotherapy and Pharmacology 43(6):445-453, 1999.
  24. Egorin, M.J., E.G. Zuhowski, D.L. Sentz, J.M. Dobson, P.S. Callery and J.L. Eiseman. Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 [NSC 676418], a silicone phthalocyanine photodynamic sensitizing agent. Cancer Chemotherapy and Pharmacology 44(4):283-294, 1999.
  25. Figg, W.D., S. Raje, K.S. Bauer, A. Tompkins, D. Venzon, R. Bergan, A. Chen, M. Hamilton, J. Pluda and E. Reed. Pharmacokinetics of thalidomide in an elderly prostate cancer population. Journal of Pharmaceutical Sciences 88(1):121-125, 1999.
  26. Fullerton, T., D. Komorowski-Swiatek, A. Forrest and F.M. Gengo. The pharmacodynamics of sumatriptan in nitroglycerin-induced headache. Journal of Clinical Pharmacology 39(1):17-29, 1999.
  27. Ghosh D., T.A. Deisher and J.L Ellsworth. Statistical methods for analyzing repeated measures. Journal of Pharmacological and Toxicological Methods42(3):157-162, 1999.
  28. Gidding, C.E.M., G.J. Meeuwsen-de Boer, P. Koopmans, D.R.A. Uges, W.A. Kamps and S.S.N. de Graaf. Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemotherapy and Pharmacology 44(3):203-209, 1999.
  29. Hakman, M. and T. Groth. Object-oriented biomedical system modeling – The Rationale. Computer Methods and Programs in Biomedicine 59(1):1-17, 1999.
  30. Jolin, J.A., P.R. Hutson and J.C. Schink. Methotrexate sequestration in an ovarion cyst. Gynecologic Oncology 72(1):113-115, 1999.
  31. Kumar, S., G.R. Tonn, K.W. Riggs and D.W. Rurak. Diphenhydramine disposition in the sheep maternal-placental-fetal unit: Determinants of plasma drug concentrations in the mother and the fetus. Journal of Pharmaceutical Sciences 88(12):1259-1265, 1999.
  32. Krzyzanski, W., R. Ramakrishnan and W.J. Jusko. Basic pharmacodynamic models for agents that alter production of natural cells. Journal of Pharmacokinetics and Biopharmaceutics 27(5):467-489, 1999.
  33. Luzier, A.B., A. Killian, J.H. Wilton, M.F. Wilson, A. Forrest and D.J. Kazierad. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clinical Pharmacology and Therapeutics 66(6):594-601, 1999.
  34. Machado, S.G., R.Miller and C. Hu. A regulatory perspective on pharmacokinetic/pharmacodynamic modelling. Statistical Methods in Medical Research 8(3):217-245, 1999.
  35. Mahmood, I. and H. Mahayni. A limited sampling approach in bioequivalence studies: application to long half-life drugs and replicate design studies. International Journal of Clinical Pharmacology and Therapeutics 37(6):275-281, 1999.
  36. Margolis, D., A. Heredia, J. Gaywee, D. Oldach. G. Drusano and R. Redfield. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 21(5):362-370, 1999.
  37. Merkus, D., F. Kajiya, H. Vink, I. Vergroesen, J. Dankelman, M. Goto and J.A.E. Spaan. Prolonged diastolic time fraction protects myocardial perfusion when coronary blood flow is reduced. Circulation 100(1):75-81, 1999.
  38. Miyazaki, M., Y. Fujiwara, T. Isobe, M. Yamakido, T. Kato and H. Miyazaki. The relationship between Carboplatin AUC and serum thrombopoietin kinetics in patients with lung cancer. Anticancer Research 19(1B):667-670, 1999.
  39. Murry, D.J., C.M. Oermann, C.N. Ou, C. Rognerudk, D.K. Seilheimer and M.M. Sockrider. Pharmacokinetics of ibuprofen in patients with cystic fibrosis. Pharmacotherapy 19(3):340-345, 1999.
  40. Newman, M.S., G.T. Colbern, P.K.Working, C. Engbers and M.A. Amantea. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemotherapy and Pharmacology 43(1):1-7, 1999.
  41. Parker, J.D., J.J. Thiessen, R. Reilly, J.H. Tong, D.J. Stewart and A.S. Pandey. Human endothelin-1 clearance kinetics revealed by a radiotracer technique. Journal of Pharmacology and Experimental Therapeutics 289(1):261-265, 1999.
  42. Peloquin, C.A., R. Namdar, A.A. Dodge and D.E. Nix. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. International Journal of Tuberculosis and Lung Disease 3(8):703-710, 1999.
  43. Peloquin, C.A., A.E. Bulpitt, G.S. Jaresko, R.W. Jelliffe, J.M. Childs and D.E. Nix. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrobial Agents and Chemotherapy 43(3):568-572, 1999.
  44. Peloquin, C.A., R. Namdar, M.D. Singleton and D.E. Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115(1):12-18, 1999.
  45. Perry, J.J., R.A. Fleming, M.V. Rocco, W.P. Petros, A.J. Bleyer, J.E. Radford, B.L. Powel and D.D. Hurd. Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease. Bone Marrow Transplantation 23(8):839- 842, 1999.
  46. Preston, S.L., G.L. Drusano, P. Glue, J. Nash. S.K. Gupta and P. McNamara Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrobial Agents and Chemotherapy 43(10):2451- 2456, 1999.
  47. Ramanathan, M. A method for estimating pharmacokinetic risks of concentrationdependent drug interactions from preclinical data. Drug Metabolism and Disposition 27(12):1479-1487, 1999.
  48. Rodman, J.H., P.M. Flynn, B. Robbins, E. Jimenez, A.D. Bardeguez, J.F. Rodriguez, S. Blanchard and A. Fridland. Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1-infected women and newborn infants. Journal of Infectious Diseases 180(6):1844-1850, 1999.
  49. Schalla, M. and M. Weiss. Pharmacokinetic curve fitting using numerical inverse Laplace transformation. European Journal of Pharmaceutical Sciences 7(4):305-309, 1999.
  50. Schoenmakers, I., H.A.W. Hazewinkel and W.E. van den Brom. Excessive Ca and P intake during early maturation in dogs alters Ca and P balance without long-term effects after dietary normalization. Journal of Nutrition 129(5):1068-1074, 1999.
  51. Siegel, J.A., S.R. Thomas, J.B. Stubbs, M.G. Stabin, M.T. Hays, K.F. Koral, J.S. Robertson, R.W. Howell, B.W. Wessels, D.R. Fisher, D.A. Weber, A.B. and A.B. Brill. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. Journal of Nuclear Medicine 40(2):37S-61S, 1999.
  52. Smith, M.V. and W.F. McDonnell. A statistical model for FEV1 response to arbitrary dynamic ozone exposure conditions. Journal of the Air and Waste Management Association 49(3):289-298, 1999.
  53. Smith, T.J., T.A. Jennings, D. Sciaky and H.J. Cao. Prostaglandin-endoperoxide H synthase-2 expression in human thyroid epithelium – Evidence for constitutive expression in vivo and in cultured KAT-50 cells. Journal of Biological Chemistry 274(22):15622- 15632, 1999.
  54. Snoeck, E., P. Jacqmin, A. Van Peer and M. Danhof. A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine. Journal of Pharmacokinetics and Biopharmaceutics 27(3):257-281, 1999.
  55. Sowinski, K.M., S.R. Abel, W.R. Clark and B.A. Mueller. Effect of gender on the pharmacokinetics of ofloxacin. Pharmacotherapy 19(4):442-446, 1999.
  56. Sparano, J.A., J. Speyer, W.J. Gradishar, L. Liebes, R. Sridhara, S. Mendoza, D. Fry and M.J. Egorin. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. Journal of Clinical Oncology 17(3):880-886, 1999.
  57. Stowe, C.D. and S.J. Phelps. Altered clearance of theophylline in children with Down syndrome: A case series. Journal of Clinical Pharmacology 39(4):359-365, 1999.
  58. Suarez-Kurtz, G., F.A. Bozza, F.L. Vicente, C.G. Ponte and C.J. Struchiner. Limited sampling strategy models for itraconazole and hydroxy-itraconazole based on data from a bioequivalence study. Antimicrobial Agents and Chemotherapy 43(1):134-140, 1999.
  59. Sun, Y.N., H.J. Lee, R.R. Almon and W.J. Jusko. A pharmacokinetic pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys. Journal of Pharmacology and Experimental Therapeutics 289(3):1523-1532, 1999.
  60. Sun, Y.N., L.I. McKay, D.C. DuBois, W.J. Jusko and R.R. Almon. Pharmacokinetic/ pharmacodynamic models for corticosteroid receptor down-regulation and glutamine synthetase induction in rat skeletal muscle by a receptor/gene-mediated mechanism. Journal of Pharmacology and Experimental Therapeutics 288(2):720-728, 1999.
  61. Sun, Y.N. and W.J. Jusko. Role of baseline parameters in determining indirect pharmacodynamic responses. Journal of Pharmaceutical Sciences 88(10):987-990, 1999.
  62. Tang, D.L., C. Yang and D.N. Ku. A 3-D thin-wall model with fluid-structure interactions for blood flow in carotid arteries with symmetric and asymmetric stenoses. Computers and Structures 72(1-3):357-377, 1999.
  63. Terziivanov, D., I. Atanasova, V. Dimitrova, R. Robeva, S. Unger and W. Muck. Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis. International Journal of Clinical Pharmacology and Therapeutics 37(8):404- 412, 1999.
  64. Thompson, J., E.O. George, C.A. Poquette, P.J. Cheshire, L.B. Richmond, S.S.N. de Graaf, M. Ma, C.F. Stewart and P.J. Houghton. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clinical Cancer Research 5(11):3617-3631, 1999.
  65. Tranchand, B., C. Amsellem, E. Chatelut, G. Freyer, A. Iliadis, B. Ligneau, V. Trillet- Lenoir, P. Canal, I. Lochon and C.J. Ardiet. A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients. Cancer Chemotherapy and Pharmacology 43(4):316-322, 1999.
  66. Vey, N., H. Kantarjian, H. Tran, M. Beran, S. O’Brien, C. Bivins, F. Giles, J. Cortes, B. Cheson, S. Arbuck and E. Estey. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia. Annals of Oncology 10(5):577-583, 1999.
  67. Williams, M.L., I.W.Wainer, L. Embree, M. Barnett, C.L. Granvil and M.P. Ducharme. Enantioselective induction of cyclophosphamide metabolism by phenytoin. Chirality 11(7):569-574, 1999.
  68. Williams, M.L., I.W. Wainer, C.P. Granvil, B. Gehrcke, M.L. Bernstein and M.P. Ducharme. Pharmacokinetics of (R)- and (S)-cyclophosphamide and their dechloroethylated metabolites in cancer patients. Chirality 11(4):301-308, 1999.
  69. Wu, A.M., L.E. Williams, L. Zieran, A. Padma, M. Sherman, G.G. Bebb, T. Odom- Maryon, J.Y.C. Wong, J.E. Shively and A.A. Raubitschek. Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging. Tumor Targeting4(1):47-58, 1999.
  70. Yu, L.X. An integrated model for determining causes of poor oral drug absorption. Pharmaceutical Research 16(12):1883-1887, 1999.
  71. Yu, L.X. and G.L. Amidon. A compartmental absorption and transit model for estimating oral drug absorption. International Journal of Pharmaceutics 186(2):119-125, 1999.
  72. Yule, S.M., L. Price, M. Cole M, A.D.J. Pearson and A.V. Boddy. Cyclophosphamide metabolism in children with Fanconi’s anaemia. Bone Marrow Transplantation 24(2):123- 128, 1999.
  73. Yule, S.M., D. Walker, M. Cole, L. McSorley, S. Cholerton, A.K. Daly, A.D.J. Pearson and A.V. Boddy. The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metabolism and Disposition 27(3):417-421, 1999.
  74. Zamboni, W.C., L.C. Bowman, M. Tan, V.M. Santana, P.J. Houghton, W.H. Meyer, C.B. Pratt, R.L. Heideman, A.J. Gajjar, A.S. Pappo and C.F. Stewart. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemotherapy and Pharmacology 43(6):454-460, 1999.
  75. Zamboni, W.C., P.J. Houghton, J.L. Hulstein, M. Kirstein, J. Walsh, P.J. Cheshire, S.K. Hanna, M.K. Danks and C.F. Stewart. Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer Chemotherapy and Pharmacology 43(4):269-276, 1999.